Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Travere Therapeutics (NASDAQ: TVTX ) recently got full approval for its sparsentan 200/400 mg tablets, branded as Filspari, for patients with IgA nephropathy (IgAN), also known as Berger's disease, a chronic kidney disease caused by the body's immune system producing abnormallyAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker ...